Anti-TNF therapy for RA in the setting of HCV appears to be safe and well tolerated, without apparent influence on the underlying HCV infection; however, the usually nonaggressive course of HCV-related arthritis does not justify the therapeutic use of anti-TNF [88]. This evidence concerns the gene TNF and arthritic joint disease.